10579 studies found for:    NCI
Show Display Options
RSS Create an RSS feed from your search for:
NCI
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Conditions: AIDS-Related Kaposi Sarcoma;   HIV Infection;   Recurrent Kaposi Sarcoma
Interventions: Drug: Bortezomib;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
2 Recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Drug: Veliparib
3 Completed Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
Conditions: Adult Fibrosarcoma;   Dermatofibrosarcoma Protuberans;   Recurrent Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
4 Active, not recruiting Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: Azacitidine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study
5 Active, not recruiting Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Conditions: Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Nodal Marginal Zone Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Vorinostat
6 Completed Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Conditions: Childhood Soft Tissue Sarcoma;   Childhood Liver Cancer;   Bone Cancer;   Brain Tumor;   Kidney Tumor
Intervention: Drug: doxorubicin HCl liposome
7 Completed Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
Conditions: Blastic Phase Chronic Myelogenous Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Relapsing Chronic Myelogenous Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: alvocidib;   Drug: vorinostat
8 Completed Interleukin-12 in Treating Patients With Advanced Cancer
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: recombinant interleukin-12
9 Completed Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Medulloepithelioma;   Childhood Mixed Glioma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Extra-adrenal Paraganglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Spinal Cord Neoplasm;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions: Drug: vorinostat;   Drug: temozolomide;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
10 Recruiting Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis
11 Completed Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Stage II Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Procedure: adjuvant therapy;   Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab
12 Completed Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Thrombocytopenia
Interventions: Drug: Alvocidib Hydrochloride;   Drug: Lenalidomide;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
13 Recruiting INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: IDO1 Inhibitor INCB024360;   Other: Laboratory Biomarker Analysis;   Procedure: Therapeutic Conventional Surgery
14 Completed SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells
Conditions: Atypical Squamous Cells of Undetermined Significance;   Cervical Cancer;   High-grade Squamous Intraepithelial Lesion;   Low-grade Squamous Intraepithelial Lesion
Interventions: Biological: HspE7;   Other: placebo;   Other: laboratory biomarker analysis
15 Active, not recruiting Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: laboratory biomarker analysis;   Other: pharmacological study
16 Completed Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung
Conditions: Breast Cancer;   Metastatic Cancer
Interventions: Biological: aldesleukin;   Biological: therapeutic tumor infiltrating lymphocytes;   Biological: trastuzumab;   Drug: paclitaxel;   Procedure: conventional surgery
17 Completed Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: atrasentan hydrochloride
18 Completed ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: fluorouracil;   Drug: gefitinib;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
19 Completed BMS-247550 in Treating Patients With Stage IV Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: ixabepilone;   Other: pharmacogenomic studies;   Other: laboratory biomarker analysis
20 Active, not recruiting Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: Bortezomib;   Other: Laboratory Biomarker Analysis;   Drug: Vorinostat

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years